Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
X. Wu, M. Go, J. V. Nguyen, N. W. Kuchel, B. G. C. Lu, K. N. Lowes, D. J. Calleja, J. P. Mitchell, G. Lessene, D. Komander, M. E. Call, M. J. Call
The paper uses Deep Mutational Scanning to analyze SARS-CoV-2 PLpro mutations, identifying functional residues and drug-escape variants.
bioRxiv · Mar 11, 2024Biochemistry
Z. Yuan, M. F. van Delft, M. X. Li, F. Sumardy, B. J. Smith, D. C. S. Huang, G. Lessene, Y. Khakham, R. Jin, S. He, N. A. Smith, R. Birkinshaw, P. E. Czabotar, G. Dewson
This study identifies key residues in the BAK:VDAC2 interaction, showing that disrupting this interaction can inhibit or promote apoptosis depending on the context.
bioRxiv · Dec 13, 2023 · PreprintCell Biology
A. W. Burgess, M. C. Faux, S. P. Corona, J. Weinstock, G. Lessene, F. Walker
The paper investigates the effectiveness of dual drug combinations in killing colon cancer cells and identifies a viable oral treatment for xenograft models.
bioRxiv · Feb 28, 2021 · PreprintCancer Biology
T. Klemm, G. Ebert, D. J. Calleja, C. C. Allison, L. W. Richardson, J. P. Bernardini, B. G. C. Lu, N. W. Kuchel, C. Grohmann, Y. Shibata, Z. Y. Gan, J. P. Cooney, M. Doerflinger, A. E. Au, T. R. Blackmore, , D. Komander
This study investigates SARS-CoV-2 PLpro's mechanism and identifies non-covalent inhibitors with antiviral activity.
bioRxiv · Jun 18, 2020Biochemistry
K. Brinkmann, P. Waring, S. Glaser, V. Wimmer, D. Nhu, L. Whitehead, A. R. Delbridge, G. Lessene, M. Herold, G. L. Kelly, S. Grabow, A. Strasser
The paper shows that BCL-XL protects adult kidneys from radiation-induced damage, leading to secondary anemia, and highlights its importance in cancer therapy combinations.
bioRxiv · Apr 28, 2020 · PreprintPharmacology & Toxicology
M. S. Brennan, C. Chang, G. Dewson, L. Tai, G. Lessene, A. Strasser, G. L. Kelly, M. J. Herold
This study develops a humanized Mcl-1 mouse model to evaluate MCL-1 inhibitors, showing improved sensitivity to S63845 and effective tumor remission in pre-clinical trials.
bioRxiv · Jun 14, 2018Cancer Biology